Applications Open | 1 December - 27 February 2026 AEDST*

*no late applications will be considered

Offer of Places for Participants | May 2026

Applications are reviewed by the Workshop Steering Committee, which bases its decisions on:

• Quality and feasibility of the proposed research concept and support letters

• Applicant’s career stage, training, and competence in clinical cancer research

• Institutional and departmental support

Decisions are final and made at the committee’s sole discretion. Applications are open primarily to those based in East Asia and Pacific regions.

Required Supporting Documents

1. Concept outline of the proposed study (using the provided template)

2. Curriculum vitae (including publication list)

3. Applicant’s letter detailing background, career goals, motivation, and commitment

4. Supervisor’s letter of support with assurance of institutional backing

Eligibility Criteria

• Open to clinical cancer researchers from any oncology-related field (e.g., medical, surgical, radiation oncology, palliative care, pathology, nursing, allied health, etc.)

• Preference for applicants near the end of training or within 5 years post-specialisation

• Applicants from other cancer research professions may be considered

• A limited number of non–Asia Pacific applicants may be accepted

• Must be fluent in English and competent with computers

• Must agree to ACORD Workshop Terms and Conditions

Assessment Criteria

• Quality and feasibility of the research proposal

• Applicant’s commitment to workshop participation

• Level of supervisory and institutional support

• Track record of both the applicant and their institution, and the potential benefit of workshop participation

Assessment Principles

• Focus on promise and potential of the idea, applicant, and support system

• Open to applicants with limited research experience, if they show enthusiasm and potential

• Preference for proposals that are feasible and scalable (e.g., starting with smaller pilot or phase 1–2 studies rather than over-ambitious phase 3 trials)

• Strength of institutional and supervisory backing and potential wider benefit of participation are considered